10,226 Shares in InfuSystem Holdings, Inc. (NYSE:INFU) Purchased by Summit Global Investments

Summit Global Investments purchased a new stake in InfuSystem Holdings, Inc. (NYSE:INFU) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 10,226 shares of the company’s stock, valued at approximately $86,000.

Other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of InfuSystem by 66.4% during the third quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after purchasing an additional 1,626 shares during the period. State Street Corp lifted its holdings in shares of InfuSystem by 1.1% during the third quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after buying an additional 3,019 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of InfuSystem by 74.1% in the third quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company’s stock valued at $104,000 after acquiring an additional 6,623 shares during the period. Geode Capital Management LLC grew its stake in shares of InfuSystem by 1.8% in the third quarter. Geode Capital Management LLC now owns 436,508 shares of the company’s stock valued at $2,925,000 after acquiring an additional 7,550 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in InfuSystem during the fourth quarter worth about $85,000. 71.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, March 14th. Sidoti raised InfuSystem to a “strong-buy” rating in a research report on Tuesday, March 18th.

InfuSystem Trading Up 1.3 %

Shares of InfuSystem stock opened at $6.15 on Wednesday. The firm’s 50-day moving average price is $7.36 and its two-hundred day moving average price is $7.55. The company has a market capitalization of $129.21 million, a price-to-earnings ratio of 102.52 and a beta of 1.75. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $5.29 and a 12-month high of $9.97.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.